Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the AVONELLE-X and SALWEEN ...

Roche announced today that it received CE mark approval for its port delivery platform containing its Susvimo therapeutic.

Paul Brunetta, M.D., joins as Chief Medical Officer; Kristen Quigley joins as Chief Clinical Operations Officer; Alpana Naresh, Ph.D., joins as ...

The company is committing over half a billion dollars to build a state-of-the-art research hub in Thousand Oaks, CA, designed ...

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in ...

August 2025 brought significant advancements in biosimilars, including financial successes, new product launches, and research on ongoing challenges in market access.

The OMass partnership will boost Roche’s strategy in inflammatory bowel diseases, currently led by afimkibart, an anti-TL1A ...

Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program. | Roche’s Genentech unit has handed over ...

Omass Therapeutics Ltd. has entered into an exclusive collaboration and license agreement with Genentech Inc., a member of the Roche Group, for the rights to develop and commercialize Omass’ ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ...

The global Food Allergy Immunotherapy Market is projected to grow from USD 99.7 million in 2025 to USD 249.3 million by 2035, reflecting an incremental gain of USD 149.6 million and a compound annual ...